1. Home
  2. EYPT

as of 11-28-2025 12:54pm EST

$14.74
$0.05
-0.37%
Stocks Industrials Biotechnology: Laboratory Analytical Instruments Nasdaq

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Chart Type:
Time Range:
Founded: 1987 Country:
United States
United States
Employees: N/A City: WATERTOWN
Market Cap: 967.4M IPO Year: 2005
Target Price: $29.60 AVG Volume (30 days): 1.3M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.00 EPS Growth: N/A
52 Week Low/High: $3.91 - $14.96 Next Earning Date: 11-05-2025
Revenue: $42,339,000 Revenue Growth: -7.38%
Revenue Growth (this year): -13.63% Revenue Growth (next year): -56.51%

AI-Powered EYPT Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 74.66%
74.66%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of EyePoint Pharmaceuticals Inc. (EYPT)

Ribeiro Ramiro

Chief Medical Officer

Sell
EYPT Nov 11, 2025

Avg Cost/Share

$11.61

Shares

2,722

Total Value

$31,602.42

Owned After

0

SEC Form 4

Share on Social Networks: